LETTER TO THE EDITOR Performance of the ViroSeq® HIV-1 Genotyping System v2.0 in Central Africa
Linda Chapdeleine Mekue Mouafo 1, 2, Hélène Péré 2, 3, Angélique Ndjoyi-Mbiguino 4, Donato Koyalta 5, Jean De Dieu Longo 6, François-Xavier Mbopi-Kéou 7, Coumba Toure Kane 8, Laurent Bélec*, 2, 3
Identifiers and Pagination:Year: 2015
First Page: 9
Last Page: 13
Publisher ID: TOAIDJ-9-9
Article History:Received Date: 12/11/2014
Revision Received Date: 1/1/2015
Acceptance Date: 12/1/2015
Electronic publication date: 27 /2/2015
Collection year: 2015
open-access license: This is an open access article licensed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted, non-commercial use, distribution and reproduction in any medium, provided the work is properly cited.
Resistance genotypes in pol gene of HIV-1 were obtained by the ViroSeq® HIV-1 Genotyping System v2.0 (Celera Diagnostics, Alameda, CA, USA) in 138 of 145 (95%) antiretroviral treatment-experienced adults in virological failure living in Central Africa (Cameroon, Central African Republic, Chad, Gabon). HIV-1 group M exhibited broad genetic diversity. Performance of the 7 ViroSeq® sequencing primers showed high failure rate, from 3% to 76% (D: 76%; F: 17%; A and H: 15%; G and B: 4%; C: 3%). These findings emphasize the need of updating the ViroSeq® HIV-1 genotyping system for non-B subtypes HIV-1.